Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals Inc.
WKN: 881535 / Symbol: REGN / Name: Regeneron / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
981,40 €
-0,08 %
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $1,150.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Royal Bank of Canada from $1,185.00 to $1,200.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Royal Bank of Canada from $1,200.00 to $1,229.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,150.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1,229.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Argus from $1,060.00 to $1,170.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Barclays PLC from $1,050.00 to $1,200.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $1,183.00 to $1,182.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Guggenheim from $1,040.00 to $1,180.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at TD Cowen from $1,030.00 to $1,200.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Neueste Beiträge
Truist_Financial_Co_ in Genuine Parts Corp diskutieren